Literature DB >> 17614351

Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells.

Ana C Donadio1, Carolina Lobo, Marta Tosina, Vanessa de la Rosa, Mercedes Martín-Rufián, José A Campos-Sandoval, José M Matés, Javier Márquez, Francisco J Alonso, Juan A Segura.   

Abstract

Glutamine behaves as a key nutrient for tumors and rapidly dividing cells. Glutaminase is the main glutamine-utilizing enzyme in these cells, and its activity correlates with glutamine consumption and growth rate. We have carried out the antisense L-type glutaminase inhibition in human MCF7 breast cancer cells, in order to study its effect on the hexosamine pathway and the pattern of protein O-glycosylation. The antisense mRNA glutaminase expressing cells, named ORF19, presented a 50% lower proliferation rate than parental cells, showing a more differentiated phenotype. ORF19 cells had an 80% reduction in glutamine:fructose-6-P amidotransferase activity, which is the rate-limiting step of the hexosamine pathway. Although the overall cellular protein O-glycosylation did not change, the O-glycosylation status of several key proteins was altered. O-glycosylation of O-GlcNAc transferase (OGT), the enzyme that links N-acetylglucosamine to proteins, was fivefold lower in ORF19 than in wild type cells. Inhibition of glutaminase also provoked a 10-fold increase in Sp1 expression, and a significant decrease in the ratio of O-glycosylated to total protein for both Sp1 and the Rpt2 proteasome component. These changes were accompanied by a higher Sp1 transcriptional activity. Proteome analysis of O-glycosylated proteins permitted the detection of two new OGT target proteins: the chaperonin TCP-1 theta and the oncogene Ets-related protein isoform 7. Taken together, our results support the hexosamine pathway and the O-glycosylation of proteins being a sensor mechanism of the nutritional and energetic states of the cell. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17614351     DOI: 10.1002/jcb.21449

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

Review 1.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

2.  Protein O-GlcNAcylation: A critical regulator of the cellular response to stress.

Authors:  John C Chatham; Richard B Marchase
Journal:  Curr Signal Transduct Ther       Date:  2010-01

Review 3.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

Review 4.  Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function.

Authors:  Victor M Darley-Usmar; Lauren E Ball; John C Chatham
Journal:  J Mol Cell Cardiol       Date:  2011-08-22       Impact factor: 5.000

Review 5.  O-GlcNAc signaling: a metabolic link between diabetes and cancer?

Authors:  C Slawson; R J Copeland; G W Hart
Journal:  Trends Biochem Sci       Date:  2010-05-11       Impact factor: 13.807

Review 6.  Therapeutic strategies impacting cancer cell glutamine metabolism.

Authors:  Michael J Lukey; Kristin F Wilson; Richard A Cerione
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 7.  The role of protein O-linked beta-N-acetylglucosamine in mediating cardiac stress responses.

Authors:  John C Chatham; Richard B Marchase
Journal:  Biochim Biophys Acta       Date:  2009-07-14

8.  Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent.

Authors:  Luyun Zou; Xiaoyuan Zhu-Mauldin; Richard B Marchase; Andrew J Paterson; Jian Liu; Qinglin Yang; John C Chatham
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

Review 9.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.

Authors:  R J DeBerardinis; T Cheng
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

10.  Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

Authors:  Hongjun Jin; Mai Xu; Prashanth K Padakanti; Yongjian Liu; Suzanne Lapi; Zhude Tu
Journal:  Mol Pharm       Date:  2013-09-03       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.